Industries > Pharma > Pharma Leader Series: Top 20 Asthma & COPD Companies 2019-2029

Pharma Leader Series: Top 20 Asthma & COPD Companies 2019-2029

Company Overview, Marketed Products, Product Pipeline, Revenues, Forecast

PUBLISHED: 19 December 2018
PAGES: 160
PRODUCT CODE: PHA0349

Clear
WOOCS 2.2.1

The global asthma & COPD therapies market was valued at $36.21bn in 2018 and is projected to grow to $47bn by 2029.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 160-page report you will receive 86 charts– all unavailable elsewhere.

The 160-page report provides clear detailed insight into the Top 20 asthma & COPD companies. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

• Global Asthma & COPD Therapies Market forecasts from 2019-2029

• Profiles of the leading 20 asthma & COPD companies:
• Aerocrine (Circassia)
• ALK-Abello A/S
• Amphastar Pharmaceuticals, Inc.
• AstraZeneca
• Boehringer Ingelheim
• Chiesi Farmaceutici
• Cipla
• GlaxoSmithKline
• Lallemand Pharma International
• Merck
• MundiPharma
• Novartis
• Pulmatrix
• Roche
• Sanofi/Regeneron
• Sunovion
• Teva
• Theravance Biopharma|Mylan Inc.
• Vectura Group plc
• Verona Pharma plc

Top 20 Asthma & COPD Companies 2019-2029

• The content of each profile differs, depending on the organization. In general, a profile gives the following information:
• An overview and analysis of the company
• A portfolio of the company’s marketed product and product pipeline
• Financial Information
• Revenue forecast from 2019-2029
• Recent developments
• Future Outlook

• This report discusses factors that drive and restrain the asthma and COPD market.

Visiongain’s study is intended for anyone requiring commercial analyses for the top 20 asthma & COPD therapies companies. You find data, trends and predictions.

Buy our report today Pharma Leader Series: Top 20 Asthma & COPD Companies 2019-2029: Company Overview, Marketed Products, Product Pipeline, Revenues, Forecast

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Download sample pages

Complete the form below to download your free sample pages for Pharma Leader Series: Top 20 Asthma & COPD Companies 2019-2029


Download sample pages

Complete the form below to download your free sample pages for Pharma Leader Series: Top 20 Asthma & COPD Companies 2019-2029


Latest Pharma news

The Global Wound Care Market Is Set to Boom, Particularly in Emerging Economies

The global wound care market is big, and only set to grow bigger.  Currently, estimates show a CAGR of 4.6% in the years to come, with the overall market growing from 19.8 billion in 2019 to 24.8 billion by 2024.  The industry is ripe with opportunity, with that growth coming from several factors – but most especially growth in emerging …

30 March 2020

READ

“The global nasal drug delivery technology market is estimated to have reached $44,385 million in 2019” says new Visiongain report

Nasal Sprays segment held the largest market share of the global nasal drug delivery technology market in 2019.

30 March 2020

READ

“Global Stem Cell Technologies and Applications market set to grow to $10903.0m by 2025” says new Visiongain report

New technologies will be needed to ensure that scaling-up of manufacturing operations can be done effectively once stem cell treatments enter the market.

24 March 2020

READ

Visiongain publishes Novel Coronavirus (COVID-19) Drugs in Development Market Forecast 2020-2030 report

As per the latest reports of UNCTAD (United Nations Conference on Trade and Development), COVID-19 pandemic has not only led to tragic human consequences but is projected to cost the global economy $1 trillion in 2020.

24 March 2020

READ

Categories

Category